Business / Finance

RSS

Spherix closes private placement transaction

Spherix Incorporated – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today announced the closing of previously announced agreements to sell $1.25 million of shares of its common stock together with warrants to purchase additional shares of its common stock in a private placement transaction.

29 Oct 2011

Intrexon acquires Immunologix

SCRA, on behalf of its SC Launch program, today announced that Portfolio Company Immunologix has been acquired by Virginia-based synthetic biology company Intrexon Corporation. The Charleston-based Immunologix team is now part of Intrexon's Protein Production Division.

29 Oct 2011

Standard Register reports revenue of $157.5 million for third quarter 2011

Standard Register today announced its financial results for the third quarter. The Company reported revenue of $157.5 million and a net profit of $8.4 million, or $0.29 per diluted share.

29 Oct 2011

Pfizer acquires Icagen

Pfizer Inc. announced today that it has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer.

29 Oct 2011

LifePoint Hospitals third quarter revenues increase 5.4% to $877.2 million

LifePoint Hospitals, Inc. today announced results for the third quarter and nine months ended September 30, 2011.

28 Oct 2011

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its third quarter 2011 results.

28 Oct 2011

Amerigroup reports net income of $48.1 million for third quarter 2011

Amerigroup Corporation today announced that net income for the third quarter of 2011 was $48.1 million, or $0.96 per diluted share, versus net income of $84.3 million, or $1.68 per diluted share, for the third quarter of 2010 and compared to $44.3 million, or $0.83 per diluted share, for the second quarter of 2011.

28 Oct 2011

DiaGenic reports operating revenue of NOK 276 thousand for third quarter 2011

DiaGenic has successfully finalized the first clinical study in collaboration with Pfizer, the market leader for Alzheimer's therapeutics sales and Pfizer has confirmed DiaGenic's findings resulting in a press release October 14th.

28 Oct 2011

ICON third quarter net revenues increase 7% to $241 million

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the third quarter ended September 30, 2011.

27 Oct 2011

Elan's third quarter total revenue increases 17% to $328.5 million

Elan Corporation, plc today reported its third quarter and first nine months 2011 financial results.

27 Oct 2011

CompCare to distribute innovative lumbar traction DDS belt in the U.S., Canada and Puerto Rico

Comprehensive Care Corporation, which provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the U.S., today announced that it has acquired exclusive distribution rights to an innovative patented product aimed directly at reducing depression in individuals resulting from chronic back pain.

24 Oct 2011

Cigna enters definitive agreement to acquire HealthSpring for $55 per share

Cigna Corporation and HealthSpring, Inc. today announced that they have signed a definitive agreement under which Cigna will acquire all the outstanding shares of HealthSpring for $55 per share in cash, a 37% premium over the closing stock price on Friday October 21, 2011, representing a total transaction value of approximately $3.8 billion.

24 Oct 2011

US markets for neurosurgical and neurovascular devices to grow to $240 million by 2016

According to Millennium Research Group, the global authority on medical technology market intelligence, the market for the specialized devices used for neurosurgical and neurovascular treatments will grow to $240 million by 2016, driven largely by an aging population in the United States that will suffer an increasing incidence of conditions such as stroke, cerebral aneurysms and intracranial atherosclerosis disease.

From Medtronic 24 Oct 2011

Premier awards Lantheus three-year supplier agreement for nuclear imaging products

Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced it has been awarded a three-year supplier contract with Premier Purchasing Partners, L.P., the group purchasing unit of the Premier healthcare alliance, for its radiopharmaceutical imaging agents.

24 Oct 2011

Zynex ranked 127th on Deloitte's 2011 Technology Fast 500 list

Zynex, Inc., a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced that it has been ranked 127th on Deloitte's 2011 Technology Fast 500 list for revenue growth between 2006 and 2010.

24 Oct 2011

Aetna and Carilion Clinic launch Whole Health plans for Roanoke-area businesses

Aetna and Carilion Clinic have launched a suite of new health benefit plans - called Aetna Whole Health - now available to Virginia employers with two to 100 eligible employees.

24 Oct 2011

Encision second quarter total revenue increases 14% to $3.267 million

Encision Inc., a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its second fiscal quarter ended September 30, 2011.

24 Oct 2011

Cubist signs definitive agreement to acquire Adolor

Cubist Pharmaceuticals, Inc. and Adolor Corporation today announced that they have signed a definitive agreement under which Cubist will acquire all of the outstanding shares of Adolor for $4.25 per share in cash, or approximately $190 million on a fully-diluted basis, net of Adolor's third quarter 2011 cash balance.

24 Oct 2011

Arrowhead acquires RNA therapeutics assets from Roche

Arrowhead Research Corporation, today announced that it has acquired RNA therapeutics assets from Roche including the state-of-the-art research site in Madison, WI.

24 Oct 2011

Allos terminates AMAG merger agreement with AMAG

Allos Therapeutics, Inc. announced today that the Agreement and Plan of Merger and Reorganization entered into by and among Allos, AMAG and Alamo Acquisition Sub, Inc. on July 19, 2011, as amended on August 8, 2011, has been terminated.

22 Oct 2011